Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting
Company plans to showcase new volumetric MERFISH datasets in mouse brain and human neurodegenerative brain tissue, generated on the existing MERSCOPE Ultra™ Platform
Vizgen, Inc., a leader in spatial multiomics and developer of the MERSCOPE Ultra™ Platform, today announced it will debut a 3D Volumetric Tissue Mapping dataset in neurodegenerative brain tissue using MERFISH 2.0™ chemistry on the MERSCOPE Ultra Platform at the Human Cell Atlas (HCA) General Meeting, June 16-18, in Boston. The company will also launch Volumetric Tissue Mapping services and a new Cell Atlasing Hub, a central resource for the cell atlasing community offering public datasets, case studies, and expert consultation.
The HCA General Meeting convenes the global cell atlasing community at a pivotal moment, as the field works to translate foundational atlases into deeper biological and disease insight. Vizgen is introducing Volumetric Tissue Mapping now to give that community a path to add the third dimension to their work, capturing the cellular context, tissue architecture, and disease microenvironments that cell atlasing depends on but that thin-section approaches cannot resolve.
